Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Epperly CorinneOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Ho William Tai-WeiOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:502,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Goswami TrishnaOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:176,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Rochlin KateOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:186,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Lamb LawrenceOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:169,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:McCall PatrickOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:189,000Price:--
-
Dec 15, 2023 (filed on Dec 15, 2023)Insider Name:Bios Clinical Opportunity Fund, LPOwnership Type:Direct OwnershipSecurities:Series B WarrantNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 15, 2023 (filed on Dec 15, 2023)Insider Name:Bios Clinical Opportunity Fund, LPOwnership Type:Direct OwnershipSecurities:Series A WarrantNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 15, 2023 (filed on Dec 15, 2023)Insider Name:Bios Clinical Opportunity Fund, LPOwnership Type:Direct OwnershipSecurities:Pre-Funded WarrantsNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 13, 2023 (filed on Dec 15, 2023)Insider Name:Graff Jeremy R.Ownership Type:Direct OwnershipSecurities:Series B Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,049Price:--
Filings by filing date
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Epperly CorinneOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Ho William Tai-WeiOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:502,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Goswami TrishnaOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:176,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Rochlin KateOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:186,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:Lamb LawrenceOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:169,000Price:--
-
Feb 07, 2024 (filed on Feb 08, 2024)Insider Name:McCall PatrickOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:189,000Price:--
-
Dec 13, 2023 (filed on Dec 15, 2023)Insider Name:Graff Jeremy R.Ownership Type:Direct OwnershipSecurities:Series B Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,049Price:--
-
Dec 13, 2023 (filed on Dec 15, 2023)Insider Name:Graff Jeremy R.Ownership Type:Direct OwnershipSecurities:Series A Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,049Price:--
-
Dec 13, 2023 (filed on Dec 15, 2023)Insider Name:Graff Jeremy R.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,049Price:--
-
Dec 13, 2023 (filed on Dec 15, 2023)Insider Name:Epperly CorinneOwnership Type:Direct OwnershipSecurities:Series B Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:81,967Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Empire State Building 350 5Th Avenue, Suite 5330 NEW YORK NY 10118 |
Tel: | N/A |
Website: | https://www.in8bio.com |
IR: | See website |
Key People | ||
William T. Ho President, Chief Executive Officer, Director | Lawrence S. Lamb Co-Founder, Executive Vice President, Chief Scientific Officer | Patrick Mccall Chief Financial Officer |
Kate Rochlin Chief Operating Officer | Trishna Goswami Chief Medical Officer |
Business Overview |
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company's DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types. |
Financial Overview |
For the fiscal year ended 31 December 2023, IN8BIO, Inc. revenues was not reported. Net loss increased 5% to $30M. Higher net loss reflects Research and development increase of 18% to $14.9M (expense), Stock-based Compensation in R&D increase of 35% to $1.9M (expense), Stock-based Compensation in SGA increase of 20% to $2.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.36 to -$1.00. |
Employees: | 31 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $25.82M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$28.44M as of Dec 31, 2023 |
Net annual income (TTM): | -$30.01M as of Dec 31, 2023 |
Free cash flow (TTM): | -$23.94M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 43,287,325 as of Mar 14, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |